| Literature DB >> 19327145 |
Abstract
BACKGROUND: The discovery of novel protein biomarkers is essential in the clinical setting to enable early disease diagnosis and increase survivability rates. To facilitate differential expression analysis and biomarker discovery, a variety of tandem mass spectrometry (MS/MS)-based protein profiling techniques have been developed. For achieving sensitive detection and accurate quantitation, targeted MS screening approaches, such as multiple reaction monitoring (MRM), have been implemented.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19327145 PMCID: PMC2670839 DOI: 10.1186/1471-2407-9-96
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Figure 1Proteomic maps. (A) Theoretical distribution of the human proteins according to the SwissProt database (~25,000 genes); (B) Experimental distribution of the 1,572 proteins from the MCF-7 library (all proteins were identified with p < 0.001 and ≥ 2 spectral counts).
Figure 2Charts that illustrate the impact of protein size on likelihood of detection. (A) Chart illustrating the distribution of observable (theoretical) tryptic peptides as a function of protein MW, for the set of 1,572 proteins; (B) Chart illustrating the ratio of the experimental percentage of identified proteins to the theoretical percentage of proteins vs. the number of amino acids in a protein. The experimental protein percentages were calculated relative to the total number of identified proteins, and the theoretical percentages were calculated relative to the total number of proteins in the SwissProt database.
Figure 3Charts that illustrate protein abundance as a function of protein MW, for the set 1,572 proteins. (A) Chart illustrating protein abundance as a function of MW in terms of experimental protein sequence coverage; (B) Chart illustrating protein abundance as a function of MW in terms of observed/observable unique peptides; (C) Chart illustrating protein abundance as a function of MW in terms of spectral counts/observed unique peptides.
MRM transition chart for the identification of putative protein biomarkers.
| Protein/Peptides | z | -10lg(p) | Spectral count | MRM range (min) | Transitions (MH+ → product ions) |
|---|---|---|---|---|---|
| GLLSDSMTDVPVDTGVAAR | 2 | 91 | 2 | 40-90 | 952.47→(885.3, 1019.2, 1200.3, 1099.2, 574.3) |
| VVGDRENGSDNLPSSAGSGDKPLSDPAPF ( | 3 | 136 | 15 | 0-240 | 962.45→(1312.0, 1228.1, 1127.0, 1256.3, 815.9) |
| LGLSTLGELKQNLSR ( | 2 | 114 | 5 | 0-240 | 814.97→(1044.3, 617.3, 745.3, 673.4, 1157.4) |
| TPAVEGLTEAEEEELRAELTKVEEEIVTLR | 3 | 300 | 8 | 145-170 | 1128.58→(1508.1, 1443.7, 1358.6, 1063.0, 1244.1) |
| LAEQAERYEDMAAFMK | 2 | 112 | 4 | 40-90 | 951.94→(1205.2, 698.1, 1478.2, 795.4, 1625.2) |
| VLSSIEQKSNEEGSEEKGPEVR ( | 3 | 133 | 9 | 0-240 | 811.06→(740.6, 1110.0, 966.5, 1080.0, 557.2) |
| SGTIFDNFLITNDEAYAEEFGNETWGVTK | 3 | 300 | 25 | 125-145 | 1090.16→(1512.0, 1424.0, 1462.1, 991.2,1289.7) |
| FYGDEEKDKGLQTSQDAR | 2 | 141 | 13 | 0-40 | 1043.98→(1841.9, 803.6, 975.5, 1112.6, 1104.6) |
| IDNSQVESGSLEDDWDFLPPKK | 3 | 85 | 14 | 0-240 | 840.40→(981.9, 1146.5, 932.8, 1089.3, 1204.0) |
| ADLLLSTQPGREEGSPLELER | 3 | 84 | 5 | 40-90 | 770.73→(706.2, 893.3, 900.6, 842.4, 1004.3) |
| IKVAEDEAEAAAAAK | 2 | 94 | 5 | 0-240 | 743.89→(1245.2, 1146.1, 946.1, 831.1, 1075.1) |
| ISVNNVLPVFDNLMQQK | 2 | 119 | 22 | 90-125 | 980.02→(1219.3, 1332.3, 880.5, 610.1, 724.2) |
| LVDQNIFSFYLSRDPDAQPGGELMLGGTDSK | 3 | 300 | 23 | 0-240 | 1124.21→(1261.3, 1344.6, 1055.2, 1016.1, 1579.6) |
| AQALEDLAGFKELFQTPGHTEELVAAGK ( | 3 | 71 | 1 | 0-240 | 990.84→(1208.4, 1080.1, 604.9, 1386.6, 924.7) |
| SGGSGHAVAEPASPEQELDQNKGK ( | 3 | 44 | 1 | 0-240 | 798.38→(956.0,870.9, 643,2, 921.0, 653.1) |
| ATPLSSTVTLSMSADVPLVVEYK ( | 2 | 106 | 4 | 0-240 | 1204.63→(847.2, 1561.2, 1061.2, 1437.3, 538.1) |
| FSASGELGNGNIK ( | 2 | 98 | 7 | 0-240 | 647.32→(716.1, 744.2, 546.1, 902.2, 989.2) |
| LSQTSNVDKEEEAVTIEMNEPVQLTFALR ( | 3 | 101 | 5 | 0-240 | 1097.88→(1559.1, 1551.3, 1393.6, 1467.1, 937.4) |
| YYLAPKIEDEEGS ( | 2 | 112 | 8 | 0-240 | 757.35→(1003.5, |
| DLSHIGDAVVISCAK ( | 2 | 113 | 4 | 0-240 | 764.39→(962.2, |
| NLAMGVNLTSMSK ( | 2 | 35 | 5 | 0-240 | 683.34→( |
Peptides or proteins marked with "no ID" were not detectable in the whole protein extract by data dependent MS analysis. Transitions that did not result in peptide identification in the EIC are marked in bold.
Figure 4Extracted ion chromatograms illustrating five MRM transitions/peptide for the identification of putative cancer biomarkers in whole cellular extracts. Conditions: MCF-7 whole cellular extracts were digested with trypsin, cleaned-up with SPEC-PTSCX and SPEC-PTC18 cartridges, and analyzed by a ~4 h long LC-MS/MS gradient. The top-down order of EICs reflects the order of the five transitions shown in Table 1.